Well, let’s start with the obvious, a pattern that has been set for a good few years now: There were no M&A deals on the so-called Merger Monday that typically kick-started the J.P. Morgan Healthcare Conference of old.
In terms of M&A, if this pattern continues in the new decade, we should rename it Mundane Monday. There was a pre-JPM deal, namely the $1.1 billion buyout of dermatology biotech Dermira from Eli Lilly, but that wasn’t causing a stir.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,